The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) reached all time high today, Oct, 11 and still has $166.13 target or 28.00% above today’s $129.79 share price. This indicates more upside for the $26.30B company. This technical setup was reported by Barchart.com. If the $166.13 PT is reached, the company will be worth $7.36 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 175,191 shares traded hands. Zimmer Biomet Holdings Inc (NYSE:ZBH) has risen 32.01% since March 8, 2016 and is uptrending. It has outperformed by 22.70% the S&P500.
Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on November, 3. They expect $1.79 earnings per share, up 9.15% or $0.15 from last year’s $1.64 per share. ZBH’s profit will be $362.72M for 18.13 P/E if the $1.79 EPS becomes a reality. After $2.02 actual earnings per share reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts -11.39% negative EPS growth.
Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage
Out of 15 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 12 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 80% are positive. $155 is the highest target while $105 is the lowest. The $130.57 average target is 0.60% above today’s ($129.79) stock price. Zimmer Biomet Holdings has been the topic of 22 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Monday, November 2. Nomura initiated Zimmer Biomet Holdings Inc (NYSE:ZBH) rating on Thursday, March 17. Nomura has “Buy” rating and $123 price target. The firm earned “Buy” rating on Friday, July 29 by Needham. As per Wednesday, November 4, the company rating was initiated by Sterne Agee CRT. Needham maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) rating on Friday, January 29. Needham has “Buy” rating and $129 price target. The stock has “Buy” rating given by Canaccord Genuity on Friday, September 4. Suntrust Robinson initiated Zimmer Biomet Holdings Inc (NYSE:ZBH) on Thursday, August 11 with “Buy” rating. The rating was upgraded by Argus Research on Wednesday, May 25 to “Buy”. The firm earned “Sell” rating on Thursday, November 12 by Citigroup. UBS initiated Zimmer Biomet Holdings Inc (NYSE:ZBH) on Tuesday, September 22 with “Neutral” rating.
According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”
More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Forbes.com which released: “Ex-Dividend Reminder: Piedmont Natural Gas, Zimmer Biomet Holdings and Pembina …” on September 19, 2016, also Prnewswire.com with their article: “Zimmer Biomet Completes Tender Offer for Outstanding Shares of LDR Holding …” published on July 13, 2016, Wsj.com published: “Zimmer Biomet to Buy Fellow Medical Device Maker LDR Holding” on June 07, 2016. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Prnewswire.com and their article: “Zimmer Biomet Holdings to Present at INVESTIndiana Equity Conference” published on September 01, 2016 as well as Prnewswire.com‘s news article titled: “Zimmer Biomet Contributes Additional $100000 in Funding to the Orthopaedic …” with publication date: September 22, 2016.
ZBH Company Profile
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.